MEDICINOVA INC Reports Board and Officer Changes
Ticker: MNOV · Form: 8-K · Filed: Apr 1, 2024 · CIK: 1226616
Sentiment: neutral
Topics: management-change, board-of-directors, executive-officers
TL;DR
MEDICINOVA INC reshuffled its board and exec team on March 26th.
AI Summary
On March 26, 2024, MEDICINOVA, INC. filed an 8-K report detailing changes in its board of directors and executive officers. The filing indicates the departure of certain officers and directors, the election of new directors, and adjustments to compensatory arrangements for key personnel. These changes are effective as of March 26, 2024.
Why It Matters
Changes in a company's board of directors and executive officers can signal shifts in strategy, governance, or operational focus, potentially impacting future performance and investor confidence.
Risk Assessment
Risk Level: medium — Changes in leadership can introduce uncertainty regarding future strategy and execution, warranting closer monitoring.
Key Numbers
- 001-33185 — SEC File Number (Identifies the company's filing history with the SEC.)
- 33-0927979 — IRS Employer Identification No. (Company's tax identification number.)
Key Players & Entities
- MEDICINOVA INC (company) — Registrant
- March 26, 2024 (date) — Date of earliest event reported
- DELAWARE (jurisdiction) — State of incorporation
- LA JOLLA, CA (location) — Principal executive offices
FAQ
What specific roles were affected by the departure of directors or officers?
The filing indicates the departure of 'certain officers' and 'directors' but does not specify the exact roles in this section of the 8-K.
When were the new directors elected?
The filing reports on the election of directors as of March 26, 2024.
What is the company's principal executive office address?
The principal executive offices are located at 4275 EXECUTIVE SQUARE, SUITE 300, LA JOLLA, CA 92037.
What is the SIC code for MEDICINOVA INC?
The Standard Industrial Classification (SIC) code for MEDICINOVA INC is 2834, which corresponds to Pharmaceutical Preparations.
What is the effective date of the reported changes?
The earliest event reported is dated March 26, 2024, and the date as of change is also March 26, 2024.
Filing Stats: 470 words · 2 min read · ~2 pages · Grade level 10.7 · Accepted 2024-04-01 16:06:34
Key Financial Figures
- $0.001 — ection 12(b) of the Act: Common Stock, $0.001 par value MNOV The Nasdaq Stock Mar
Filing Documents
- d818300d8k.htm (8-K) — 24KB
- 0001193125-24-083356.txt ( ) — 143KB
- mnov-20240326.xsd (EX-101.SCH) — 3KB
- mnov-20240326_lab.xml (EX-101.LAB) — 18KB
- mnov-20240326_pre.xml (EX-101.PRE) — 11KB
- d818300d8k_htm.xml (XML) — 4KB
From the Filing
8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K Current Report Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 26, 2024 MEDICINOVA, INC. (Exact name of registrant as specified in its charter) DELAWARE 001-33185 33-0927979 (State or other jurisdiction of incorporation) (Commission File Number) (I.R.S. Employer Identification No.) 4275 EXECUTIVE SQUARE , SUITE 300 , LA JOLLA , CA 92037 (Address of principal executive offices) (Zip Code) Registrant's telephone number, including area code: (858) 373-1500 Not applicable. (Former name or former address, if changed since last report.) Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below): Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) Securities registered pursuant to Section 12(b) of the Act: Common Stock, $0.001 par value MNOV The Nasdaq Stock Market LLC (Title of each class) (Trading symbol(s)) (Name of each exchange on which registered) Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (240.12b-2 of this chapter). Emerging growth company If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. Item5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. Resignation of Vice President On March 26, 2024, Geoffrey O'Brien informed MediciNova, Inc. (the "Company") of his decision to retire from full-time employment and resign from his employment with the Company, effective as of April 2, 2024. Mr. O'Brien's resignation is voluntary and is not the result of any disagreement with the Company. Mr. O'Brien and the Company plan to enter into a consulting relationship whereby Mr. O'Brien would continue to serve as Vice President of the Company on a consulting basis. The Company expects to enter into a consulting agreement with Mr. O'Brien to formalize that relationship. SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. MEDICINOVA, INC. By: /s/ Yuichi Iwaki Yuichi Iwaki President and Chief Executive Officer Date: April 1, 2024